Clinical Trial Update: Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure. [Phase 2, Phase 3]

View source ↗

Summary

APhase 2/3 trial evaluating LVAD combined with allogeneic mesenchymal stem cell implantation in end-stage heart failure was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Ischemic Cardiomyopathy

Drugs mentioned

• Allogeneic mesenchymal stem cells (mesenchymal stem cells)
• Left Ventricular Assist Device (LVAD) (Left Ventricular Assist Device)

Snippet

Sponsor: AHEPA University Hospital | Conditions: Heart Failure, Ischemic Cardiomyopathy | Phase 2, Phase 3 | Status: TERMINATED